Search

Your search keyword '"Virus et Immunité - Virus and immunity"' showing total 2 results
Start Over Author "Virus et Immunité - Virus and immunity" Publisher public library of science
2 results on '"Virus et Immunité - Virus and immunity"'

1. Interplay between SARS-CoV-2 and the type I interferon response

Author

Marlène Dreux, Margarida Sa Ribero, Nolwenn Jouvenet, Sébastien Nisole, Trafic Vésiculaire, Réponse Innée et Virus – Vesicular trafficking, Innate response, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Research in the laboratory of NJ is funded by the CNRS, the Institut Pasteur, the European Molecular Biology Organisation (EMBO) Young Investigator Program, and the Agence Nationale de la Recherche Scientifique (ANR 16 CE15 0025 01 VIRO-STORM). Research related to the topic of this review in the team led by MD is supported by the Agence Nationale de la Recherche (ANR Flash COVID-19 and ANR 19-CE15-0025-01 JCJC iSYN). Research related to the topic of this review in the team led by SN is supported by the Labex EpiGenMed, an Investissements d’avenir program (ANR-10-LABX-12-01), the Région Occitanie and the Agence Nationale de la Recherche (ANR Flash COVID-19)., ANR-16-CE15-0025,Viro-Storm,Mécanismes de production incontrôlée de cytokines au cours de l'infection virale(2016), ANR-10-LABX-0012,EpiGenMed,From Genome and Epigenome to Molecular Medicine: turning new paradigms in biology into the therapeutic strategies of tomorrow(2010), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Bodescot, Myriam, Mécanismes de production incontrôlée de cytokines au cours de l'infection virale - - Viro-Storm2016 - ANR-16-CE15-0025 - AAPG2016 - VALID, Laboratoires d'excellence - From Genome and Epigenome to Molecular Medicine: turning new paradigms in biology into the therapeutic strategies of tomorrow - - EpiGenMed2010 - ANR-10-LABX-0012 - LABX - VALID, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Virus et Immunité - Virus and immunity (CNRS-UMR3569)

Subjects
RNA viruses, Viral Diseases, Pulmonology, Coronaviruses, viruses, Disease, Review, medicine.disease_cause, Biochemistry, Medical Conditions, Interferon, Biology (General), Pathology and laboratory medicine, Coronavirus, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, 0303 health sciences, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, 030302 biochemistry & molecular biology, virus diseases, Medical microbiology, Prognosis, 3. Good health, STAT proteins, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Viruses, Interferon Type I, [SDV.IMM]Life Sciences [q-bio]/Immunology, SARS CoV 2, Pathogens, Coronavirus Infections, COVID-19, Respiratory infections, Interferons, SARS coronavirus, Viral replication, SARS-CoV-2, STAT protein, medicine.drug, [SDV.IMM] Life Sciences [q-bio]/Immunology, QH301-705.5, Immunology, Pneumonia, Viral, Biology, Microbiology, Antiviral Agents, Proinflammatory cytokine, 03 medical and health sciences, Respiratory Disorders, Betacoronavirus, Immune system, Immunity, Virology, Genetics, medicine, Humans, Molecular Biology, Pandemics, 030304 developmental biology, Medicine and health sciences, Biology and life sciences, Organisms, Viral pathogens, Proteins, Covid 19, Dendritic Cells, RC581-607, Viral Replication, Immunity, Innate, respiratory tract diseases, Microbial pathogens, COVID-19 Drug Treatment, Respiratory Infections, Parasitology, Immunologic diseases. Allergy
Abstract

International audience; The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current COVID-19 pandemic. An unbalanced immune response, characterized by a weak production of type I interferons (IFN-Is) and an exacerbated release of proinflammatory cytokines, contributes to the severe forms of the disease. SARS-CoV-2 is genetically related to SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV), which caused outbreaks in 2003 and 2013, respectively. Although IFN treatment gave some encouraging results against SARS-CoV and MERS-CoV in animal models, its potential as a therapeutic against COVID-19 awaits validation. Here, we describe our current knowledge of the complex interplay between SARS-CoV-2 infection and the IFN system, highlighting some of the gaps that need to be filled for a better understanding of the underlying molecular mechanisms. In addition to the conserved IFN evasion strategies that are likely shared with SARS-CoV and MERS-CoV, novel counteraction mechanisms are being discovered in SARS-CoV-2-infected cells. Since the last coronavirus epidemic, we have made considerable progress in understanding the IFN-I response, including its spatiotemporal regulation and the prominent role of plasmacytoid dendritic cells (pDCs), which are the main IFN-I-producing cells. While awaiting the results of the many clinical trials that are evaluating the efficacy of IFN-I alone or in combination with antiviral molecules, we discuss the potential benefits of a well-timed IFN-I treatment and propose strategies to boost pDC-mediated IFN responses during the early stages of viral infection.

Published
2020
Full Text
View/download PDF

2. Neonatal Plasmacytoid Dendritic Cells (pDCs) Display Subset Variation but Can Elicit Potent Anti-Viral Innate Responses

Author

Xiaoming Zhang, Claude Leclerc, Pierre Lebon, Richard Lo-Man, Gwenaelle Roguet, Elie Azria, Olivier Schwartz, Odile Launay, Alice Lepelley, Institut Pasteur de Shanghai, Académie des Sciences de Chine - Chinese Academy of Sciences (IPS-CAS), Réseau International des Instituts Pasteur (RIIP), Régulation Immunitaire et Vaccinologie, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Sorbonne Paris Cité (USPC), Department of Obstetrics and Gynecology, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC - Biotherapie - AP-HP (cochin - Pasteur), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), ANR-09-MIEN-0017,NEOSYK,ETUDE DES DES VOIES SYK ET MYD88 POUR L'ACTIVATION EFFICACE DU SYSTEME IMMUNITAIRE NEONATAL(2009), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur in Shanghai - Chinese Academy of Sciences ( IPS-CAS ), Réseau International des Instituts Pasteur ( RIIP ) -Institut Pasteur de Shanghai - Académie des Sciences de Chine, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Virus et Immunité, Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Université Sorbonne Paris Cité ( USPC ), AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), CHU Cochin [AP-HP], Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), ANR-09-MIEN-0017,NEOSYK,ETUDE DES DES VOIES SYK ET MYD88 POUR L'ACTIVATION EFFICACE DU SYSTEME IMMUNITAIRE NEONATAL ( 2009 ), ANR-10-LABX-62-IBEID,IBEID,Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases' ( 2010 ), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), ANR-10-LABX-62-IBEID,IBEID,Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases'(2010), and Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris]

Subjects
Chemokine, [SDV]Life Sciences [q-bio], lcsh:Medicine, [ SDV.IMM.IA ] Life Sciences [q-bio]/Immunology/Adaptive immunology, medicine.disease_cause, 0302 clinical medicine, Influenza A virus, lcsh:Science, Immune Response, Cells, Cultured, 0303 health sciences, education.field_of_study, Multidisciplinary, biology, Interleukin-12 Subunit p40, hemic and immune systems, Middle Aged, Flow Cytometry, Innate Immunity, 3. Good health, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Oligodeoxyribonucleotides, Cord blood, Chemokines, Research Article, Adult, Adolescent, Population, Immunology, CD2 Antigens, CD5 Antigens, Virus, 03 medical and health sciences, Immune system, medicine, Humans, education, Biology, Immunity to Infections, 030304 developmental biology, [ SDV ] Life Sciences [q-bio], Tumor Necrosis Factor-alpha, lcsh:R, Immunity, Infant, Newborn, TLR9, Interferon-alpha, Immune Defense, TLR7, Dendritic Cells, Virology, Immunity, Innate, Toll-Like Receptor 7, Toll-Like Receptor 9, biology.protein, lcsh:Q, 030215 immunology
Abstract

International audience; Neonates are highly susceptible to infectious diseases and defective antiviral pDC immune responses have been proposed to contribute to this phenomenon. Isolated cord blood pDCs innately responded to a variety of TLR7 and TLR9 dependent viruses, including influenza A virus (IAV), human immunodeficiency virus (HIV) or herpes-simplex virus (HSV) by efficiently producing IFN-α, TNF-α as well as chemokines. Interestingly, following activation by CpGA, but not viruses, cord pDCs tend to survive less efficiently. We found that a hallmark of pDCs in neonates is an extended CD2+pDCs compartment compared to adult pDCs without affecting the antiviral IFN-α response. Within CD2+pDCs, we identified a subpopulation expressing CD5 and responsible for IL-12p40 production, however this population is significantly decreased in cord blood compared to adult blood. Therefore, neonatal pDCs clearly display variation in phenotype and subset composition, but without major consequences for their antiviral responses.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results